Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Pembrolizumab is currently used to treat advanced triple-negative breast cancer (TNBC) and high-risk early TNBC with neoadjuvant chemotherapy (NAC). The tumor-infiltrating lymphocyte (TIL) level and programmed cell death ligand 1 (PD L1) status are predictors of response to NAC and immune checkpoint inhibitor treatment. We aimed to investigate whether the PD-L1 status in core needle biopsies (CNBs) could represent the whole tumor in TNBC. Materials and Methods: A total of 49 patients diagnosed with TNBC who received upfront surgery without NAC between January 2018 and March 2021 were included. The PD-L1 expression (SP142 and 22C3 clones) and TIL were evaluated in paired CNBs and resected specimens. The concordance PD-L1 status and TIL levels between CNBs and resected specimens were analyzed. Results: PD-L1 positivity was more frequently observed in resected specimens. The overall reliability of TIL level in the CNB was good [intraclass correlation coefficient (ICC)=0.847, p<0.001]. The agreements of PD-L1 status were good and fair, respectively (SP142, κ=0.503, p<0.001; 22C3, κ=0.380, p=0.010). As the core number of CNB increased, the reliability and agreement also im proved, especially from five tumor cores (TIL, ICC=0.911, p<0.001; PD-L1 [22C3], κ=0.750, p=0.028). Regarding PD-L1 (SP142), no further improvement was observed with ≥5 tumor cores (κ=0.600, p=0.058). Conclusion: CNBs with ≥5 tumor cores were sufficient to represent the TIL level and PD-L1 (22C3) status in TNBC.
Abstract
Purpose: Pembrolizumab is currently used to treat advanced triple-negative breast cancer (TNBC) and high-risk early TNBC with neoadjuvant chemotherapy (NAC). The tumor-infiltrating lymphocyte (TIL) level and programmed cell death ligand 1 (PD L1) status are predictors of response to NAC and immune checkpoint inhibitor treatment. We aimed to investigate whether the PD-L1 status in core needle biopsies (CNBs) could represent the whole tumor in TNBC. Materials and Methods: A total of 49 patients diagnosed with TNBC who received upfront surgery without NAC between January 2018 and March 2021 were included. The PD-L1 expression (SP142 and 22C3 clones) and TIL were evaluated in paired CNBs and resected specimens. The concordance PD-L1 status and TIL levels between CNBs and resected specimens were analyzed. Results: PD-L1 positivity was more frequently observed in resected specimens. The overall reliability of TIL level in the CNB was good [intraclass correlation coefficient (ICC)=0.847, p<0.001]. The agreements of PD-L1 status were good and fair, respectively (SP142, κ=0.503, p<0.001; 22C3, κ=0.380, p=0.010). As the core number of CNB increased, the reliability and agreement also im proved, especially from five tumor cores (TIL, ICC=0.911, p<0.001; PD-L1 [22C3], κ=0.750, p=0.028). Regarding PD-L1 (SP142), no further improvement was observed with ≥5 tumor cores (κ=0.600, p=0.058). Conclusion: CNBs with ≥5 tumor cores were sufficient to represent the TIL level and PD-L1 (22C3) status in TNBC.
참고문헌 (31)
- Symmans WF, "Longterm prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype", J Clin Oncol, 35, pp.1049~1060 (2017)
- Lotfinejad P, "Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL)and programmed death ligand 1 (PD-L1) expression in triple-negative breast cancer (TNBC): a systematic review and meta-analysis study", Diagnostics(Basel), 10, pp.704~ (2020)
- Gao G, "Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer : a systematic review and meta-analysis", BMC Cancer, 20, pp.179~ (2020)
- Ono M, "Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer", Breast Cancer Res Treat, 132, pp.793~805 (2012)
- Yi M, "Combination strategies with PD-1", PD-L1 blockade : current advances and future directions, 2022, pp.21, 28~
- Schmid P, "Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer", N Engl J Med, 379, pp.2108~2121 (2018)
- Cortes J, "Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer(KEYNOTE-355) : a randomised, placebo-controlled, double-blind, phase 3 clinical trial", Lancet, 396, pp.1817~1828 (2020)
- Marra A, "Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy", Cancer J, 27, pp.41~49 (2021)
- Mittendorf EA, "Neoadjuvant atezolizumab in combination with sequential nabpaclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer(IMpassion031) : a randomised, double-blind, phase 3 trial", Lancet, 396, pp.1090~1100 (2020)
- Schmid P, "Pembrolizumab for early triple-negative breast cancer", N Engl J Med, 382, pp.810~821 (2020)
- Balar AV, "PD-1 and PD-L1 antibodies in cancer : current status and future directions", Cancer Immunol Immunother, 66, pp.551~564 (2017)
- Kos Z, "Pitfalls in assessing stromal tumor infiltrating lymphocytes(sTILs)in breast cancer", NPJ Breast Cancer, 6, pp.17~ (2020)
- Cha YJ, "Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens : a retrospective analysis", Breast Cancer Res Treat, 171, pp.295~302 (2018)
- Stovgaard ES, "PD-L1 diagnostics in the neoadjuvant setting : implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies", Breast Cancer Res Treat, 181, pp.553~560 (2020)
- Dobritoiu F, "Tissue selection for PD-L1 testing in triple negative breast cancer(TNBC)", Appl Immunohistochem Mol Morphol, 30, pp.549~556 (2022)
- Salgado R, "The evaluation of tumor-infiltrating lymphocytes(TILs)in breast cancer : recommendations by an International TILs Working Group 2014", Ann Oncol, 26, pp.259~271 (2015)
- Loi S, "Tumor-infiltrating lymphocytes and prognosis : a pooled individual patient analysis of early-stage triple-negative breast cancers", J Clin Oncol, 37, pp.559~569 (2019)
- Hammond ME, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, 2010, pp.28, 2784~2795
- Wolff AC, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, 2007, pp.25, 118~145
- Vennapusa B, "Development of a PD-L1 complementary diagnostic immunohistochemistry assay(SP142)for atezolizumab", Appl Immunohistochem Mol Morphol, 27, pp.92~100 (2019)
- Koo TK, "A guideline of selecting and reporting intraclass correlation coefficients for reliability research", J Chiropr Med, 15, pp.155~163 (2016)
- Landis JR, "The measurement of observer agreement for categorical data", Biometrics, 33, pp.159~174 (1977)
- Buisseret L, "Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer", Mod Pathol, 30, pp.1204~1212 (2017)
- Khoury T, "Tumor-infiltrating lymphocytes in breast cancer : evaluating interobserver variability, heterogeneity, and fidelity of scoring core biopsies", Am J Clin Pathol, 150, pp.441~450 (2018)
- Mani NL, "Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer", Breast Cancer Res, 18, pp.78~ (2016)
- Rugo HS, "PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer", J Natl Cancer Inst, 113, pp.1733~1743 (2021)
- Park S, "Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non–small-cell lung cancer", J Clin Oncol, 40, pp.1916~1928 (2022)
- Lee J, "Current treatment landscape for early triple-negative breast cancer(TNBC)", J Clin Med, 12, pp.1524~ (2023)
- Fassler DJ, "Spatial characterization of tumor-infiltrating lymphocytes and breast cancer progression", Cancers(Basel), 14, pp.2148~ (2022)
- Fernandez-Martinez A, "Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2", HER2-positive breast cancer : a correlative analysis of the CALGB 40601 and PAMELA trials, 2023, pp.9, 490~499
- Burstein MD, "Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer", Clin Cancer Res, 21, pp.1688~1698 (2015)